<DOC>
	<DOC>NCT01423305</DOC>
	<brief_summary>The objective of the study is to assess if charcoal prevents the absorption of budesonide and formoterol via GI track. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve.</brief_summary>
	<brief_title>Phase I Pharmacokinetic Study (BF-BLOCK)</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>1. Healthy males and females aged 1860 years. 2. Normal weight at least 50 kg. 1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolicendocrine, neurological or psychiatric disease. 2. Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study. 3. Any condition requiring concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. 4. Known hypersensitivity to the active substance(s) or the excipients of the drug. 5. Pregnant or lactating females.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Asthma</keyword>
</DOC>